Number of patients
(n = 37)

Autologous PBSCT group II (n = 13)

Allogeneic BMT group III (n = 24)


Mean age (years)

48.15 ± 12.67^{b}

36.00 ± 16.08

Male

10

12

Female

03^{b}

12

Diagnosis
  
Multiple myeloma

03

01

Lymphoma Hodgkin

05

03

Lymphoma No Hodgkin

02

02

Leukemia
  
Leukemia Acute myeloid

01

02

Leukemia Chronic myeloid

00

07

Leukemia Acute lymphoblastic

01

01

Leukemia Chronic lymphoid

00

01

Myelodysplasia

00

05

Aplastic anemia

00

02

Tumor Ewing

01

00

Conditioning regimen
  
BuCy 120

01

13

BuCy 200

01

00

M200

04

01

CBV

04

00

FluCy

00

05

BEAM

02

00

CyTBI

01

03

another

00

02

 The CR patients were divided according to diseases. M200: melphalan (200 mg/m^{2}) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT. CBV: cyclophosphamide (1500 mg/m^{2}) given 4 consecutive days starting 6 days before the transplantation (days minus 6 to minus 3) + carmustine (BCNU – 450 mg/m^{2}) given only 1 day before the transplantation (day minus 6) + etoposide (VP16 – 250 mg/m^{2}) given 3 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 4) or BEAM: carmustine (BCNU – 300 mg/m^{2}) given only 1 day before the transplantation (day minus 7) + etoposide (VP16 – 200 mg/m^{2}) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + cytarabine (100 mg/m^{2}) given 4 consecutive days two times a day, starting 6 days before the transplantation (days minus 6 to minus 3) + melphalan (140 mg/m^{2}) given only 1 day before the transplantation (day minus 6) for Hodgkin and nonHodgkin lymphomas in autologous PBSCT. FluCy: fludarabine (30 mg/m^{2}) + cyclophosphamide (300 mg/m^{2}), both given 3 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2) for Hodgkin and nonHodgkin lymphomas in allogeneic BMT. BuCy120: busulphan (1 mg/kg), given 4 consecutive days four times a day, starting 8 days before the transplantation (days minus 8 to minus 5) + cyclophosphamide (60 mg/kg), given 2 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 3) for acute and chronic myeloid leukemia and syndrome mielodysplastic in autologous PBSCT or allogeneic BMT. BuCy200: busulphan (1 mg/kg), given 3 consecutive days four times a day, starting 9 days before the transplantation (days minus 9 to minus 7) + cyclophosphamide (50 mg/m^{2}), given 4 consecutive days, starting 6 days before the transplantation (days minus 6 to minus 3) for aplastic anemia in allogeneic BMT. CyTBI: cyclophosphamide (60 mg/m^{2}), given 2 consecutive days, starting 7 days before the transplantation (days minus 7 to minus 6) + total body irradiation, carried out on 4 consecutive days, starting 4 days before the transplantation (days minus 4 to minus 2, three times a day and day minus 1, two times a day) for acute and chronic lymphoid leukemia in autologous PBSCT or allogeneic BMT. All patients had 2 rest days (without chemotherapy) before the transplantation (days minus 2 and minus 1), except FluCy and CyTBI CR patients, that had only one rest day (day minus 1 and minus 5, respectively).

^{b} Significantly different between groups II (autol.) and III (allog.).